Efficacy and safety of daprodustat in Japanese peritoneal dialysis patients

Daprodustat is a hypoxia‐inducible factor‐prolyl hydroxylase inhibitor for the treatment of anemia of chronic kidney disease. This phase 3 study evaluated the efficacy and safety of daprodustat in an uncontrolled cohort of 56 Japanese peritoneal dialysis patients with anemia over 52 weeks. Subjects...

Descripción completa

Detalles Bibliográficos
Autores principales: Kanai, Hidetoshi, Nangaku, Masaomi, Nagai, Reiko, Okuda, Nobuhiko, Kurata, Kyo, Nagakubo, Takashi, Endo, Yukihiro, Cobitz, Alexander
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons Australia, Ltd 2021
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9290017/
https://www.ncbi.nlm.nih.gov/pubmed/33964183
http://dx.doi.org/10.1111/1744-9987.13686

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9290017/
https://www.ncbi.nlm.nih.gov/pubmed/33964183
http://dx.doi.org/10.1111/1744-9987.13686

Ejemplares similares